ReviewFrontiers in pediatrics2018
Microbial Transglutaminase Is Immunogenic and Potentially Pathogenic in Pediatric Celiac Disease.
Review in Frontiers in pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Factors associated with adherence to gluten-free diet among celiac patients in Palestine: a cross-sectional study.Scientific reports · 2026Article
- Genetically Modified Microorganisms: Risks and Regulatory Considerations for Human and Environmental Health.Microorganisms · 2026Review
- Microbial transglutaminase in food biotechnology: from biochemical mechanisms to industrial applications.Applied microbiology and biotechnology · 2026Review
- Effect of a Gluten-Free Diet on the Intestinal Microbiota of Women with Celiac Disease.Antibiotics (Basel, Switzerland) · 2025Article
- Microbial Transglutaminase-The Food Additive, a Potential Inducing Factor in Primary Biliary Cholangitis.Molecules (Basel, Switzerland) · 2025Article
- The Potential Harmful Effects of Genetically Engineered Microorganisms (GEMs) on the Intestinal Microbiome and Public Health.Microorganisms · 2024Review
- Safety evaluation of the food enzyme protein-glutamine γ-glutamyltransferase from the non-genetically modifiedEFSA journal. European Food Safety Authority · 2024Article
- pH and Thrombin Concentration Are Decisive in Synthesizing Stiff, Stable, and Open-Porous Fibrin-Collagen Hydrogel Blends without Chemical Cross-Linker.Advanced healthcare materials · 2023Article
- Microbiological transglutaminase: Biotechnological application in the food industry.Open life sciences · 2023Review
- Defective humoral immunity disrupts bile acid homeostasis which promotes inflammatory disease of the small bowel.Nature communications · 2022Article
- Gluten-free diet exposure prohibits pathobiont expansion and gluten sensitive enteropathy in B cell deficient JH-/- mice.PloS one · 2022Article
- Review
- Review
- Alpha-enolase involvement in intestinal and extraintestinal manifestations of celiac disease.Journal of translational autoimmunity · 2021Article
- Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?Pharmaceutics · 2020Review
- A recent update on the use of microbial transglutaminase for the generation of biotherapeutics.World journal of microbiology & biotechnology · 2020Review
- Antibodies against neo-epitope of microbial and human transglutaminase complexes as biomarkers of childhood celiac disease.Clinical and experimental immunology · 2020Article
- Processed Food Additive Microbial Transglutaminase and Its Cross-Linked Gliadin Complexes Are Potential Public Health Concerns in Celiac Disease.International journal of molecular sciences · 2020Review
- Microbial transglutaminase should be considered as an environmental inducer of celiac disease.World journal of clinical cases · 2019Article
- The Revival of the Battle between David and Goliath in the Enteric Viruses and Microbiota Struggle: Potential Implication for Celiac Disease.Microorganisms · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The enzyme microbial transglutaminase is heavily used in the food processing industries to ameliorate food qualities and elongate the products' shelf life. As a protein's glue, it cross-links gliadin peptides, creating neo-complexes that are immunogenic and potentially pathogenic to celiac disease communities. Even lacking sequence identity, it imitates functionally the endogenous tissue transglutaminase, known to be the autoantigen of celiac disease and representing an undisputable key player in celiac disease initiation and progress. The present review expend on the enzyme characteristics, exogenous intestinal sources, its cross-linking avidity to gluten or gliadin, turning naïve protein to immunogenic ones. Several observation on microbial transglutaminase cross linked complexes immunogenicity in celiac patients are reviewed and its pathogenicity is summarized. Warnings on its potential risks for the gluten dependent conditions are highlighted. When substantiated, it might represent a new environmental factor of celiac disease genesis. It is hoped that the presented knowledge will encourage further research to explore the mechanism and the pathogenic pathways taken by the gliadin cross linked enzyme in driving celiac disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.